Clinical Trial Update: NAC for Attenuation of COVID-19 Symptomatology [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is updating on N-acetylcysteine (NAC) for attenuation of COVID-19 symptomatology, with various COVID-19-related respiratory conditions …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Lower Respiratory Infection
• COVID-19 Pneumonia
• COVID-19 Respiratory Infection
• Oxidative Stress
• Sars-associated Coronavirus As Cause of Disease Classified Elsewhere
• Sars-cov-2 Acute Respiratory Disease

Drugs mentioned

• N-acetylcysteine (N-acetylcysteine)

Snippet

Sponsor: Cambridge Health Alliance | Conditions: Covid19, COVID-19 Pneumonia | Phase 2 | Status: UNKNOWN